Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/QAD.0000000000001970 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A three-in-one, long-acting, nanosuspension reformulation of off-patent antiretrovirals for low-income and middle-income countries.
AIDS
November 2018
Department of Infectious Diseases, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy.
Objective: To characterize a drug-combination nanoparticle (DcNP) containing water-insoluble lopinavir (LPV) and efavirenz (EFV), and water-soluble tenofovir (TFV), for its potential as a long-acting combination HIV treatment.
Design: Three HIV drugs (LPV, EFV, TFV) with well established efficacy and safety were coformulated into a single DcNP suspension. Two macaques were administered one subcutaneous injection and drug concentrations in plasma and mononuclear cells (in peripheral blood and lymph nodes) were analyzed over 2 weeks.
Three-in-one blocks with ropivacaine: evaluation of sensory onset time and quality of sensory block.
Anesth Analg
January 2000
Department of Anesthesiology and General Intensive Care Medicine, University of Vienna, Austria.
Unlabelled: The purpose of this prospective, randomized, double-blinded study was to evaluate the sensory onset time and the quality of sensory block of ropivacaine, a new long-acting local anesthetic, compared with bupivacaine, for 3-in-1 blocks. Fifty ASA physical status I-III patients undergoing hip surgery after trauma were randomly assigned to two study groups of 25 patients each. The two study groups received a 3-in-1 block with either 20 mL of ropivacaine 0.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!